While E2F1 itself cannot currently be therapeutically targeted, the upstream kinases that positively regulate E2F1 function (cyclin‐dependent kinases 4 and 6, CDK4/6) can be inhibited (O'Leary et al, 2016), and CDK4/6 inhibitors (CDK4/6i) are under clinical investigation for a number of tumor types, including PCa (NCT02905318, NCT02494921, NCT02555189). Here, CDK4 is linked to neoplasm.